STAT3 and hepatocellular carcinoma: Studies by Cheng et al. have shown that in hepatocellular cancer-associated fibroblasts, PD-L1 expression can be induced through the IL-6-STAT3 pathway, resulting in impaired T-cell function and immune suppression through the PD1/PD-L1 signaling pathway [26–29].